BioSpace News Archive

OSSIO, Inc., a fast-growing orthopedic fixation technology company, on Friday received “breaking” news from the U.S. Food and Drug Administration (FDA).

Apellis Pharmaceuticals, Inc., announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract, a post-hoc analysis of two multicenter, placebo-controlled, Phase III studies evaluating amisulpride (a selective dopamine D2/D3 antagonist) as an antiemetic in patients with established postoperative nausea and vomiting, has been selected for a poster presentation at the 77th PGA (PostGraduate Assembly in Anesthesiology), being held December 8-11, 2023, in New York City.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium (“SABCS”).

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, highlighted the presentation of analytical and clinical validation data on a novel prognostic test in early-stage lung cancer, generated through collaboration with the Samsung Medical Centre and AstraZeneca (LSE/STO/Nasdaq: AZN).

Wave Life Sciences Ltd. (Nasdaq: WVE) today announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 as a potential treatment for alpha-1 antitrypsin deficiency (AATD).

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of sixty cents per share on the $0.10 par value common stock of the company.

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors.

89bio, Inc. announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

The global artificial intelligence (AI) in drug discovery market size was estimated at USD 1,495.28 million in 2022 and is projected to reach around USD 14,518.68 million by 2032, growing at a CAGR of 20.08% between 2022 and 2032.